Bioinformatics analysis of the prognostic value of CCT6A and associated signalling pathways in breast cancer

Huang,Kai; Zeng,Yi; Xie,Yunqing; Huang,Liying; Wu,Yu

doi:10.3892/mmr.2019.10100

Bioinformatics analysis of the prognostic value of CCT6A and associated signalling pathways in breast cancer

Authors:
- Kai Huang
- Yi Zeng
- Yunqing Xie
- Liying Huang
- Yu Wu
View Affiliations

Affiliations: Department of Breast Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Surgical Laboratory, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Head and Neck Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: March 28, 2019 https://doi.org/10.3892/mmr.2019.10100
Pages: 4344-4352
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is the most frequently diagnosed type of cancer and the leading cause of cancer‑associated mortality among women worldwide. However, the molecular basis for the pathogenesis of BC requires further exploration. Recent studies have demonstrated that chaperonin‑containing TCP1 subunit 6A (CCT6A) efficiently suppresses transforming growth factor‑β‑mediated metastasis by inhibiting the function of SMAD family member 2 in lung cancer. However, the functional significance of CCT6A in other types of cancer, including BC, remains to be investigated. Therefore, this study evaluated CCT6A expression in BC samples, and further analysed its association with survival, clinicopathological parameters and related signalling pathways using online datasets. The present study indicated that CCT6A expression was significantly higher in BC tissues compared with in surrounding noncancerous tissues at both mRNA and protein levels. Furthermore, increased CCT6A expression was significantly associated with poor survival, including overall survival, relapse‑free survival, distant metastasis‑free survival and post progression survival, in patients with BC. Pathway finder analysis indicated that CCT6A was significantly associated with the cell cycle, and its expression was significantly positively correlated with cyclin (CCN)B2 and CCNA2 expression. Taken together, to the best of our knowledge, the present study is the first to indicate that CCT6A may serve a significant role in BC tumour progression.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Yu Y, Walia V and Elble RC: Loss of CLCA4 promotes epithelial-to-mesenchymal transition in breast cancer cells. PLoS One. 8:e839432013. View Article : Google Scholar : PubMed/NCBI
3	Hynes G, Kubota H and Willison KR: Antibody characterisation of two distinct conformations of the chaperonin-containing TCP-1 from mouse testis. FEBS Lett. 358:129–132. 1995. View Article : Google Scholar : PubMed/NCBI
4	Kubota H, Hynes G, Carne A, Ashworth A and Willison K: Identification of six Tcp-1-related genes encoding divergent subunits of the TCP-1-containing chaperonin. Curr Biol. 4:89–99. 1994. View Article : Google Scholar : PubMed/NCBI
5	Rommelaere H, Van Troys M, Gao Y, Melki R, Cowan NJ, Vandekerckhove J and Ampe C: Eukaryotic cytosolic chaperonin contains t-complex polypeptide 1 and seven related subunits. Proc Natl Acad Sci USA. 90:11975–11979. 1993. View Article : Google Scholar : PubMed/NCBI
6	Yam AY, Xia Y, Lin HT, Burlingame A, Gerstein M and Frydman J: Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies. Nat Struct Mol Biol. 15:1255–1262. 2008. View Article : Google Scholar : PubMed/NCBI
7	Van Hove I, Verslegers M, Hu TT, Carden M, Arckens L and Moons L: A proteomic approach to understand MMP-3-driven developmental processes in the postnatal cerebellum: Chaperonin CCT6A and MAP kinase as contributing factors. Dev Neurobiol. 75:1033–1048. 2015. View Article : Google Scholar : PubMed/NCBI
8	Brackley KI and Grantham J: Activities of the chaperonin containing TCP-1 (CCT): Implications for cell cycle progression and cytoskeletal organisation. Cell Stress Chaperones. 14:23–31. 2009. View Article : Google Scholar : PubMed/NCBI
9	von Kriegsheim A, Baiocchi D, Birtwistle M, Sumpton D, Bienvenut W, Morrice N, Yamada K, Lamond A, Kalna G, Orton R, et al: Cell fate decisions are specified by the dynamic ERK interactome. Nat Cell Biol. 11:1458–1464. 2009. View Article : Google Scholar : PubMed/NCBI
10	Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Yu M, Miller WT and Muthuswamy SK: Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci USA. 105:12463–12468. 2008. View Article : Google Scholar : PubMed/NCBI
11	Roskoski R Jr: ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res. 66:105–143. 2012. View Article : Google Scholar : PubMed/NCBI
12	Tanic N, Brkic G, Dimitrijevic B, Dedovic-Tanic N, Gefen N, Benharroch D and Gopas J: Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell lines. Anticancer Res. 26:2137–2142. 2006.PubMed/NCBI
13	Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I and Lubec G: Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci. 2:82004. View Article : Google Scholar : PubMed/NCBI
14	Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, Zhang HZ, Wu J, Liu L, Song J, et al: CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling. J Clin Invest. 127:1725–1740. 2017. View Article : Google Scholar : PubMed/NCBI
15	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrateddata-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
16	Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM and Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
17	Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shin S, Kim Y, Chul Oh S, Yu N, Lee ST, Rak Choi J and Lee KA: Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing. Oncotarget. 8:34858–34866. 2017. View Article : Google Scholar : PubMed/NCBI
19	Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
20	Győrffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
21	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
22	Jézéquel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 131:765–775. 2012. View Article : Google Scholar : PubMed/NCBI
23	Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
24	Yu Y, Shang R, Chen Y, Li J, Liang Z, Hu J, Liu K and Chen C: Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. Biomed Pharmacother. 100:108–115. 2018. View Article : Google Scholar : PubMed/NCBI
25	Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F and Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 64:1914–1921. 1989. View Article : Google Scholar : PubMed/NCBI
26	Galea MH, Blamey RW, Elston CW and Ellis IO: The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 22:207–219. 1992. View Article : Google Scholar : PubMed/NCBI
27	Li C, Du L, Ren Y, Liu X, Jiao Q, Cui D, Wen M, Wang C, Wei G, Wang Y, et al: SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res. 38:762019. View Article : Google Scholar : PubMed/NCBI
28	Pucci S, Polidoro C, Greggi C, Amati F, Morini E, Murdocca M, Biancolella M, Orlandi A, Sangiuolo F and Novelli G: Pro-oncogenic action of LOX-1 and its splice variant LOX-1Δ4 in breast cancer phenotypes. Cell Death Dis. 10:532019. View Article : Google Scholar : PubMed/NCBI
29	O'Toole SA, Selinger CI, Millar EK, Lum T and Beith JM: Molecular assays in breast cancer pathology. Pathology. 43:116–127. 2011. View Article : Google Scholar : PubMed/NCBI
30	Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, et al: Integration of genomic, transcriptomic and proteomic data identifies two biologically distinctsubtypes of invasive lobular breast cancer. Sci Rep. 6:185172016. View Article : Google Scholar : PubMed/NCBI
31	Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI